Journal Article

DKFZ-2017-03627

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.

Koerber, S. A. (First author)DKFZ* ; Slynko, A.DKFZ* ; Haefner, M. F. ; Krug, D. ; Schoneweg, C. ; Kessel, K. ; Kopp-Schneider, A.DKFZ* ; Herfarth, K. ; Debus, J.DKFZ* ; Sterzing, F. (Last author)DKFZ*

2014
BioMed Central London

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/1748-717X-9-113

Abstract: Concurrent chemotherapy and radiation therapy is the preferred standard of care for patients with anal cancer. Several studies have suggested a benefit of intensity-modulated radiation therapy (IMRT) compared with 3D-conformal radiation (3D-CRT) regarding acute toxicity. This study evaluates outcome and toxicity of patients undergoing IMRT/Tomotherapy or 3D-CRT at our institution.A cohort of 105 anal cancer patients was treated with chemoradiation or radiation alone (16.2%) between January 2000 and December 2011. 37 patients received 3D-CRT while 68 patients were treated with IMRT. Follow-up exams were performed every 3 to 6 months for a minimum of 3 years and then annually.Median follow-up was 41.4 months (2.8 - 158.4). Overall survival (OS), Progression-free survival (PFS) and local control (LC) at 3 years was 70.3%, 66.5%, 78.3% in the 3D-CRT group and 82.9%, 66.5%, 75.3% in the IMRT group without statistically significant difference. 3-year Colostomy-free survival (CFS) was 85.7% in the IMRT/Tomotherapy group and 91.8% in the 3D-CRT group (p = 0.48). No grade 4 toxicity was found in both groups. Severe (G2/3) acute skin toxicity (94.6% vs. 63.2%; p < 0.001) and acute gastrointestinal toxicity rate (67.6% vs. 47.1%; p = 0.03) was significantly higher with 3D-CRT compared to IMRT/Tomotherapy.The use of IMRT can reduce acute severe side effects of the skin and gastrointestinal tract but did not demonstrate improved results regarding OS, PFS, LC and CFS.

---

Contributing Institute(s):

1. Biostatistik (C060)
2. KKE Strahlentherapie (E050)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2014

---

Database coverage:
; ; ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---